Fig. 3

The integrated analysis and validation combined with metabolomics and network pharmacology of blood-entry constituents. A The integrated analysis. B Blood ingredient-target network. C The screening of active compounds using the natural products library. D The CCK8 experiments revealed pro-angiogenic compounds in XFZYD. n = 6, *p < 0.05, **p < 0.01, ***p < 0.001